Professor Zheng Xiaonan, Executive Chairman and Secretary-General of the China Biomedical Industry Chain Innovation and Transformation Consortium, and Chairman of the Nanjing Biomedical Industry Innovation and Transformation Center, attended the forum and delivered an opening speech.
Professor Zheng Xiaonan, Executive Vice Chairman and Secretary-General of the China Biomedical Industry Chain Innovation and Transformation Consortium, and Chairman of Nanjing Biomedical Industry Innovation and Transformation Center
The full text of Professor Zheng Xiaonan's speech is as follows:
Distinguished guests, ladies and gentlemen:
Hello everyone!
I am extremely honored to be here, together with industry leaders, investors, and academics in the biopharmaceutical field, to participate in the High-Level Forum on New Investments in Life Sciences, co-hosted by the China Biopharmaceutical Industry Chain Innovation and Transformation Consortium and Frost & Sullivan.
The biopharmaceutical industry, as a strategic emerging industry related to national economy, people's livelihood, and national security, is also a strategic high point in the new round of scientific and technological revolution and regional competition. The development of this industry cannot be separated from the support of the capital market, which has also played a key role in this process.
However, the current industry investment environment is undergoing some changes. In the investment in the biopharmaceutical sector, we have generally felt that the industry's investment environment has cooled down. But this does not mean that our industry prospects are bleak. On the contrary, I believe this is a process of the industry returning to rationality. The cyclical nature of the capital market is common, with bubbles during peaks and adjustments during troughs. The biopharmaceutical sector faces the most fundamental needs of people: the length and quality of life, the progress of society as a whole, and ultimately, all goals will return to the field of life and health. Therefore, capital technology demand will also focus on sectors related to life and health.
Today, Pudong in Shanghai, where we are located, is also the cradle of innovation and research in China's biopharmaceutical industry. The demonstration of industries that innovate through independent, open, and institutional means also originates here. It is one of the regions with the most complete industrial chains, the longest R&D pipelines, and the most outstanding new drug achievements. Since 2015, with the reform of the drug review system and the opening of the Hong Kong Stock Exchange's 18A/Sci-Tech Innovation Board, Pudong's biopharmaceutical industry has entered an era of diversified integration and open innovation. Subsequently, a series of open innovation centers such as Johnson & Johnson, Siemens, and Roche have been launched, setting off a new wave of open innovation. In 2022, the scale of Shanghai Pudong's biopharmaceutical industry had reached 330 billion yuan, nurturing a group of outstanding entrepreneurs and representative enterprises. Shanghai Pudong is a hotbed and highland for China's biopharmaceutical industry, both nationally and globally, and we hold great respect for this China's biopharmaceutical valley.
The China Biopharmaceutical Industry Chain Innovation and Transformation Consortium was established in 2021, jointly initiated by the China Pharmaceutical Industry Association, the Chinese Pharmacological Society, the Society of Independent Pharmacists, and others. Academician Chen Kaixian, the chairman of the consortium, is also a renowned scientist both domestically and internationally. The purpose of the alliance is to aim at the global trends in biopharmaceutical technology development, integrate scientific and industrial resources in biopharmaceuticals, focus on international technology transfer, accelerate innovation and transformation empowerment, disrupt innovation, and build an innovative ecosystem for the biopharmaceutical industry chain. The center has now integrated and coordinated clinical resources in the Yangtze River Delta region, collaborating with more than 30 leading hospitals, and has formed a Yangtze River Delta Clinical Research Ethics Collaboration Alliance project. It can now conduct multi-center experiments simultaneously at multiple alliance units within just over two working days, enhancing the efficiency of clinical research and development by enterprises. In promoting innovation at the source of the industry, the alliance also actively serves the transformation of research results from universities, research institutes, and hospitals, while introducing internationally leading technologies. Currently, it has established cooperation with three international institutions for cross-border technology transfer, including several European technologies such as multi-organ chips and gene editing, which have been implemented and transformed in China. In the future, it is hoped to cooperate with Frost & Sullivan to make more contributions to introducing and exporting China's domestic biopharmaceutical industry.
Today's conference organizer, Frost & Sullivan, specializes in global capital markets and corporate consulting services. They have guided nearly a thousand domestic and international companies in listing and financing on major global capital markets, making outstanding contributions to the investment, financing, and listing of China's biopharmaceutical industry. They utilize their powerful databases and expert network to help a large number of high-quality clients achieve growth and lead in innovation through their rich professional knowledge and consulting tools. At the same time, Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences, with unique core advantages in investment and financing services for the healthcare industry. In the future, the China Biopharmaceutical Industry Innovation Transformation Alliance hopes to join hands with Frost & Sullivan to integrate resources, vigorously promote industrial and capital docking, focus on supporting capital with innovative talent needs, facilitate global technology transfer, financial investment innovation incubation services, and jointly promote the high-quality development of China's biopharmaceutical industry. Moving forward towards the new era, we will forge ahead!
Finally, I wish the New Investment Summit Forum in Life Sciences a complete success. Thank you all!
